The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 53  |  Issue : 3  |  Page : 168--173

Cognitive functions in multiple sclerosis patients


El-Sayed Ali Tag El-din1, Wafik S Bahnasy1, Khaled H Rashed1, Eman R Abd El-Samad1, Atef H Teama2,  
1 Department of Neuropsychiatry, Tanta University, Tanta, Egypt
2 Department of Diagnostic Radiology, Tanta University, Tanta, Egypt

Correspondence Address:
Wafik S Bahnasy
Department of Neuropsychiatry, Tanta University, Tanta, 11511
Egypt

Abstract

Background Cognitive impairment (CI) is a common manifestation of multiple sclerosis (MS) and can occur early or late in the disease course. Objective The aim of this study was to evaluate the types and severity of CI in different MS subtypes. Patients and methods This study was conducted on 40 MS patients and 20 healthy controls. Physical disability was assessed using the Expanded Disability Status Scale and cognitive functions were assessed using the Montreal Cognitive Assessment, the Wechsler Memory Scale-Revised, the Wisconsin Card Sorting Test, and the Bender-Gestalt test. Event-related potential p300, MRI, and brain magnetic resonance spectroscopy (MRS) were also performed. Results There was significant CI in MS patients when compared with controls. The most commonly affected cognitive domain was information-processing speed, which led to impairment in memory, attention, and visuospatial and executive functions. MRS showed decreased N-acetyl aspartate (NAA)/creatine (Cr) and NAA/choline (Cho) ratios and increased Cho/Cr ratio in MS patients. Secondary progressive multiple sclerosis patients seemed to have more CI compared with other types. Conclusion CI is a common MS manifestation occurring early in the disease course and in all MS subtypes. The degree of CI is positively correlated with axonal loss in MRS, as evidenced by reduction in NAA/Cr ratio.



How to cite this article:
Tag El-din ESA, Bahnasy WS, Rashed KH, Abd El-Samad ER, Teama AH. Cognitive functions in multiple sclerosis patients.Egypt J Neurol Psychiatry Neurosurg 2016;53:168-173


How to cite this URL:
Tag El-din ESA, Bahnasy WS, Rashed KH, Abd El-Samad ER, Teama AH. Cognitive functions in multiple sclerosis patients. Egypt J Neurol Psychiatry Neurosurg [serial online] 2016 [cited 2022 Dec 1 ];53:168-173
Available from: http://www.ejnpn.eg.net/text.asp?2016/53/3/168/193067


Full Text

 Introduction



Cognitive functions comprise a group of mental processes that allow an individual to perform everyday functions such as attention, memory, language, and executive functions, which include reasoning, problem solving, decision making, visuoconstructional skills, conceptual thinking, calculations, and orientation [1].

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects over 2.5 million people worldwide and is one of the most common causes of serious neurological disabilities in young adults [2]. Physical disabilities have been extensively studied in MS; yet cognitive impairments (CIs) are still under-researched despite their high incidence and significant impact on the patient’s quality of life [3].

Event-related potential (ERP) is an objective tool for evaluating certain aspects of cognitive processing [4]. Also, magnetic resonance spectroscopy (MRS) allows better understanding of the basis of CI in MS. It can detect metabolic abnormalities that often precede structural changes and can be used to follow-up disease progression and monitor therapeutic response [5].

 Aim of the work



The aim of the study was to investigate cognitive functions in patients with MS and their relations to the severity of physical disability and disease subtype.

 Patients and methods



The study included 40 patients with definite MS as per the Polman et al. [6] criteria who attended the Department of Neuropsychiatry, Tanta University Hospital, during the period 1 July 2011 to 1 October 2013. In addition, 20 age-matched, sex-matched, and education-matched healthy individuals were included. Written consent was taken from patients and controls. The Research Ethics Committee of Tanta University Hospital approved the study. Patients having a disease affecting cognition or with contraindications to MRI were excluded from the study.

Patients and controls were subjected to full history taking and to thorough general and neurological examination using the neurological sheet of the Tanta Neuropsychiatry Department. Physical disability was assessed using the Kurtzke Expanded Disability Status Scale (EDSS) [7].

A battery of standardized neuropsychological tests covering different cognitive domains was selected, which included the Montreal Cognitive Assessment (MoCA) [8], the Wechsler Memory Scale-Revised (WMS-R) [9], the Wisconsin Card Sorting Test (WCST) [10], and the Bender-Gestalt (BG) test [11].

ERPs p300 were determined in a sound-treated room using Tracoustic Model No RE. 241 (Carolinas Sales and Service’s, 480 Hillsboro St, Ste 100, Pittsboro, NC 27312, North Carolina, USA). Pure tone audiometry was performed using GSI version 61, and immittancemetry using Interacoustic AT235H and smart EPs of intelligent hearing system software version Microsoft Windows [4].

MRI scans were taken using 1.5-T unit SYS #GEMSOW. Single voxel localization proton MRS was performed using a spin-echo mode sequence with long TE (TR/TE/average=1600/144) and short TE (TR/TE=1600/35). Water suppression was achieved with chemical shift selection technique. The size of voxels was ∼8 cm3; the voxels were placed on the chosen MS lesions away from the cerebrospinal fluid and scalp fat and others were placed in the normal-appearing white matter. Voxels of the same size were placed over the parieto-occipital periventricular white matter in the control group. The metabolites were identified and the number of peaks fitted included the chemical shift ranges restricted to 1.9–2.1 ppm for N-acetyl aspartate (NAA), 2.9–3.1 ppm for creatine (Cr), and 3.1–3.3 ppm for choline (Cho). The peak ratios were calculated from the integration of the single peak, including NAA/Cr, NAA/Cho, and Cho/Cr.

Statistical presentation and analysis was conducted using mean, SD, the Student t-test, linear correlation coefficient, and analysis of variance tests with SPSS V18.

 Results



The study included 40 MS patients: 20 with relapsing remitting multiple sclerosis (RRMS), 16 with secondary progressive multiple sclerosis (SPMS), and four with primary progressive multiple sclerosis (PPMS). Twenty-eight patients (70%) were female and 12 (30%) were male. The mean age was 33.8±10.02 years. The mean years of education was 12.45±3.08. Disease duration was 6.33±3.49 and the mean EDSS was 4.15±2.14. Twenty-three patients (57.5%) had CI with total MoCA score less than 26.

Clinical examination of the patient group revealed 16 cases (40%) with speech difficulties, 28 cases (70%) with either unilateral or bilateral optic atrophy, two cases (5%) with partial tertiary palsy, four cases (10%) with internuclear ophthalmoplegia, and 12 cases (30%) with nystagmus. Ten cases (25%) had impaired coordination, 30 cases (75%) had pyramidal signs, 10 cases (25%) had deep sensory impairment, 16 cases (40%) had urge incontinence, six male cases had weak erection, and two cases (5%) had diabetes mellitus.

The MoCA test among MS patients and controls showed significant difference in the total score (23.56±3.6 and 29±0.79, respectively) as well as in all subdomain scores except orientation, as described in [Table 1].{Table 1}

Regarding WMS-R, the four selected items showed significant decrease among MS patients when compared with controls. Mental control was 5.5±1.59 in MS patients compared with 8.6±0.68 in controls, whereas logic memory was 9.08±2.16 in MS patients compared with 15.3±0.87 in controls. Digit total was lower in MS patients than in controls (8.85±1.76 and 14.3±0.47, respectively). Associate learning was significantly diminished in MS patients than in controls (13.73±2.6 and 18.9±0.99, respectively), as shown in [Table 1].

In WCST, there was significant increase in preservative error in MS patients (11.6±6.2) compared with controls (6.7±1.45). Regarding conceptual level response, there was a significant decrease in MS patients (41.2±8.8) compared with controls (50.3±2.3). Testing trials to complete the first category showed a nonsignificant difference between MS patients (13±4.4) and controls (12.1±1.2) [Table 1].

Regarding the BG test, the copy part showed significant decrease in MS patients compared with controls (22.8±3.46 and 29.5±0.95, respectively). The recall part was also lower in MS patients than in controls (16.3±5.87 and 28.9±1.62, respectively), as shown in [Table 1].

Examination of ERP p300 showed significant prolongation of latencies in the right and left ears of MS patients (348.75±25.67 and 344.13±27.56) when compared with controls (305.38±28.77 and 301.19±31.48). ERP amplitudes were also lower in the right and left ears of MS patients (4.43±3.2 and 4.38±3.12) than in controls (9.36±3.98 and 9.13±4.16), as shown in [Table 2] and [Figure 1].{Table 2}{Figure 1}

MRI distribution of the MS plaques revealed that 28 patients (70%) had periventricular lesions, 26 (65%) had juxtacortical plaques, 10 patients (25%) had plaques in the corpus callosum, six patients (15%) had cerebellar plaques, six patients (15%) had plaques in the basal ganglia, four patients (10%) had plaques in the brainstem, and finally four patients (10%) had spinal cord lesions.

[Table 2] shows MRS among MS patients and controls with mild but statistically significant decrease in NAA/Cr ratio in MS patients (1.135±0.248) when compared with controls (1.485±0.185). There was also a statistically significant decrease in NAA/Cho ratio in MS patients (0.886±0.230) when compared with controls (1.273±0.105). In contrast, there was a statistically significant increase in Cho/Cr ratio in MS patients (1.814±0.283) compared with controls (1.166±0.102). Low NAA indicates axonal loss or dysfunction, whereas increased Cr and Cho suggest ongoing gliosis and remyelination.

The comparison between different MS subgroups showed that patients with SPMS had lower performance in neuropsychological tests and longer latencies and reduced amplitudes in ERP p300 compared with patients with PPMS and RRMS. Regarding MRS, NAA/Cr and NAA/Cho were significantly reduced, whereas Cho/Cr was significantly increased in SPMS compared with PPMS and RRMS [Table 3].{Table 3}

There were inverse correlations between physical disability of MS patients measured by EDSS and each of total MoCA score [Figure 2], all subdomains of WMS-R, recall part of the BG test [Figure 3], amplitude of ERP p300, and MRS Cho/Cr ratio. There were positive correlations between EDSS of MS patients and each of perseverative errors of WCST, latency of the ERP p300, and MRS NAA/Cr and NAA/Cho ratios. The results of this study showed that total MoCA score as a measure of the degree of CI has a direct positive correlation with each of NAA/Cr and NAA/Cho in MRS as well as in the amplitude of ERP p300. In contrast, total MoCA has inverse correlation with MRS Cho/Cr and ERP p300 latencies.{Figure 2}{Figure 3}

 Discussion



This study stated that CI in MS patients is 57.5%, which is in agreement with the results of Glanz et al. [12], who found that CI in MS patients ranges from 50 to 70%.

The mean age of MS patients in this study was 33.8±10.02 years; the mean disease duration was 6.33±3.5; 70% of patients were female; 50% had RRMS, 40% had SPMS, and 10% had PPMS. Regarding physical disability, the mean EDSS was 4.15±2.14. These results are in agreement with those of Ribeiro et al. [13].

This study revealed significant CI in MS patients measured by different neuropsychological scales and also by auditory ERP p300. There was prominent impairment of memory, attention, information-processing speed, and executive functioning, and mild impairment in visuospatial function. This is in agreement with the results of Mai et al. [14], Elwan et al. [15], and Abraham and Rege [16].

ERP is a sensitive tool for examining arousal, attention, and vigilance. This study showed longer latencies and lower amplitudes of ERP p300 in MS patients than in controls. These results are in agreement with those of Whelan et al. [17]. In contrast, Gonzalez-Rosa et al. [18] reported that the amplitude of ERP is not affected in MS patients. This difference may be due to the inclusion of more patients with RRMS and those with lower physical disability.

In this study, there were decreases in the NAA/Cr and NAA/Cho ratios and increases in the Cho/Cr ratio in MS patients in comparison with the control group. This is in agreement with Sajja et al. [5].

The results of this study showed that patients with more severe physical disabilities had more cognitive dysfunctions, more prolonged latencies, and lower amplitudes of ERPs p300 as well as more MRS changes. This is in agreement with the results of Kocer et al. [19].

The study showed that ERP p300 and MRS changes are more severe in patients with more CI. This is in agreement with the findings of Kocer et al. [19].

The study showed that CI is more pronounced in SPMS patients than in those with PPMS and RRMS. This is in agreement with the results of Falini et al. [20] and Ruet et al. [21], the former of which can be attributed to more physical disabilities, older age, and longer disease duration in the study group.

 Conclusion



Impaired cognitive functions are common MS manifestations occurring early in the disease course and occur more frequently in SPMS patients than in PPMS and RRMS patients. The most commonly affected cognitive domains are memory, attention, information-processing speed, and executive functions.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol 2009; 60:173–196.
2Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65:239–248.
3Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7:1139–1151.
4Magnié MN, Bensa C, Laloux L, Bertogliati C, Faure S, Lebrun C. Contribution of cognitive evoked potentials for detecting early cognitive disorders in multiple sclerosis. Rev Neurol (Paris) 2007; 163:1065–1074.
5Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009; 19:45–58.
6Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292–302.
7Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444–1452.
8Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695–699.
9Fischer JS. Using the Wechsler memory scale-revised to detect and characterize memory deficits in multiple sclerosis. Clin Neuropsychol 1988; 2:149–172.
10Eling P, Derckx K, Maes R. On the historical and conceptual background of the Wisconsin Card Sorting Test. Brain Cogn 2008; 67:247–253.
11Reynolds CR. The Koppitz developmental scoring system for the Bender-Gestalt test. Austin, TX: Pro-Ed Inc; 2007.
12Glanz BI, Healy BC, Rintell DJ, Jaffin SK, Bakshi R, Weiner HL. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci 2010; 290:75–79.
13Ribeiro SB, Maia DF, Ribeiro JB. Clinical and epidemiological profile of patients with MS in Uberba, Minas Gerais, Brazil. Arq Neuropsiquiat 2011; 69:184–187.
14Mai AE, Enas AK, Azza AGH, Mahy HE, Tarek E. A study of cognitive dysfunction in multiple sclerosis, neuropsychological and magnetic resonance imaging findings. Tanta MJ 2003; 31:1368–1382.
15Elwan ME, El-Sheikh WM, El-Zawawy MS, Abd El-Ghany RS. Cognitive impairment in patients with multiple sclerosis, Departments of Neurology and Radiology, Menoufiya University. Egypt J Neurol Psychiat Neurosurg 2011; 48:331–336.
16Abraham PhK, Rege PV. A study of cognitive impairments in multiple sclerosis occupational therapy perspective. Indian J Occup Ther. 2012; 44:2–12.
17Whelan R, Lonergan R, Kiiski H, Nolan H, Kinsella K, Hutchinson M et al. A high-density ERP study reveals latency, amplitude, and topographical differences in MS patients vs controls. J Neurol Sci 2010; 293:45–50.
18Gonzalez-Rosa JJ, Vazquez-Marrufo M, Vaquero E, Duque P, Borges M, Gomez CM et al. Cluster analysis of behavioural and event-related potentials during a contingent negative variation paradigm in remitting-relapsing and benign forms of multiple sclerosis. BMC Neurol 2011; 11:1–19.
19Kocer B, Unal T, Nazliel B, Biyikli Z, Yesilbudak Z, Karakas S, Irkec C. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. Neurol Sci 2008; 29:435–444.
20Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. Am J Neuroradiol 1998; 19:223–229.
21Ruet A, Deloire M, Charré-Morin J, Hamel D, Brochet B. Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology 2013; 80:1501–1508.